Endo International (ENDP) PT Set at $7.00 by Canaccord Genuity
A number of other research firms also recently issued reports on ENDP. Leerink Swann began coverage on shares of Endo International in a report on Tuesday, January 2nd. They set an outperform rating and a $12.00 price objective for the company. Mizuho reaffirmed a buy rating and set a $12.00 price objective (down from $14.00) on shares of Endo International in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $7.00 price objective on shares of Endo International and gave the stock a hold rating in a report on Thursday, January 11th. Vetr downgraded shares of Endo International from a strong-buy rating to a buy rating and set a $8.92 price objective for the company. in a report on Monday, December 18th. Finally, Zacks Investment Research downgraded shares of Endo International from a hold rating to a sell rating in a report on Monday, January 15th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Endo International has a consensus rating of Hold and an average target price of $10.32.
Endo International (NASDAQ ENDP) opened at $6.87 on Tuesday. The company has a market cap of $1,460.00, a price-to-earnings ratio of -1.24, a PEG ratio of 2.59 and a beta of 0.35. The company has a current ratio of 1.02, a quick ratio of 0.86 and a debt-to-equity ratio of 17.00. Endo International has a 1 year low of $5.77 and a 1 year high of $14.15.
Institutional investors have recently bought and sold shares of the business. Paloma Partners Management Co bought a new stake in Endo International in the fourth quarter worth $122,000. Oakbrook Investments LLC bought a new stake in Endo International in the fourth quarter worth $133,000. LMR Partners LLP bought a new stake in Endo International in the third quarter worth $148,000. Xact Kapitalforvaltning AB bought a new stake in Endo International in the fourth quarter worth $157,000. Finally, Elkfork Partners LLC bought a new stake in Endo International in the fourth quarter worth $194,000. 92.54% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) PT Set at $7.00 by Canaccord Genuity” was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.watchlistnews.com/endo-international-endp-pt-set-at-7-00-by-canaccord-genuity-2/1903249.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.